---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-013637"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:40:17.270006+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Helix Acquisition Corp. II closes $184M IPO, including full over-allotment

## Summary
- Closed IPO of 18.4M Class A shares at $10.00 each; gross proceeds $184M.
- Underwriter exercised over-allotment option in full for additional 2.4M shares.
- Sponsor purchased 509,000 private placement shares at $10.00 for $5.09M.
- Total $184M placed in trust; must complete business combination within 24 months.
- Appointed Mark C. McKenna and John Schmid as independent directors; charter amended.

## SEC filing metadata
- accession: 0001213900-24-013637
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/ea193423-8k_helixacq2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-013637
- JSON: https://secwatch.observer/filing/0001213900-24-013637.json
- Plain text: https://secwatch.observer/filing/0001213900-24-013637.txt

## Key facts
- Executive change
  John Schmid was appointed as Director at BridgeBio Oncology Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm
- Executive change
  Mark C. McKenna was appointed as Director at BridgeBio Oncology Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm
- Governance Changes
  BridgeBio Oncology Therapeutics, Inc.: Amended and restated memorandum and articles of association filed and became effective in connection with IPO (effective 2024-02-08).
  - Change: charter amendment
  - Effective: 2024-02-08
  source text: On February 8, 2024, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended Charter ”) with the Cayman Islands General Registry, effective the same day.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm
- Material Agreements
  BridgeBio Oncology Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC (effective 2024-02-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Leerink Partners LLC
  - Effective: 2024-02-08
  source text: n January 18, 2024 (as amended, the “ Registration Statement ”): ● An Underwriting Agreement, dated February 8, 2024, between the Company and Leerink Partners LLC, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.